Mount Yale Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mount Yale Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$310K	Buy	+5,494	New	+$320K	0.01%	877
2025 Q3	–	Sell	-172	Closed	-$9.46K	–	784
2025 Q2	$9.46K	Buy	+172	New	+$10.1K	﹤0.01%	1144
2018 Q4	–	Sell	-331	Closed	-$33K	–	369
2018 Q3	$33K	Hold	331	–	–	0.01%	683
2018 Q2	$31K	Hold	331	–	–	0.01%	716
2018 Q1	$27K	Buy	+331	New	+$28.4K	0.01%	720

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mount Yale Investment Advisors's BMRN Position: Q1 2026 in Review

Mount Yale Investment Advisors opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2026: 5,494 shares worth $310K. The stake represents 0.01% of the portfolio and ranks #877 among its holdings. This is a return to the name: Mount Yale Investment Advisors previously reported a position in BMRN as recently as Q2 2025.

Mount Yale Investment Advisors first reported a position in BMRN in Q1 2018 and has held it in 5 quarters since. 556 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Mount Yale Investment Advisors held 5,494 shares of BioMarin Pharmaceuticals worth $310K as of Q1 2026.
BioMarin Pharmaceuticals was a new Mount Yale Investment Advisors position in Q1 2026.
BioMarin Pharmaceuticals made up 0.01% of Mount Yale Investment Advisors's portfolio in Q1 2026, its #877 holding.
Mount Yale Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2018 and has held it in 5 quarters since.
556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Mount Yale Investment Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.